Compare ALAR & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | GDTC |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Israel | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 10.4M |
| IPO Year | 2018 | 2021 |
| Metric | ALAR | GDTC |
|---|---|---|
| Price | $1.66 | $0.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 108.3K | 49.6K |
| Earning Date | 05-28-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.51 | N/A |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.68 |
| 52 Week High | $18.00 | $3.68 |
| Indicator | ALAR | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 24.64 | N/A |
| Support Level | $1.62 | N/A |
| Resistance Level | $2.10 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 9.09 | 0.00 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.